ACRIVON THERAPEUTICS INC. - COMMON STOCK

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

14 May 2024 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

24 Apr 2024 16:01:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

16 Apr 2024 20:01:49 By Nasdaq GlobeNewswire

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368

10 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Announces $130 Million Private Placement Financing

09 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

28 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

05 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors

04 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

27 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors

08 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Jan 2024 16:00:24 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

04 Jan 2024 08:00:01 By Nasdaq GlobeNewswire

Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer

03 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

21 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

21 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

09 Nov 2023 08:01:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

16 Oct 2023 08:00:01 By Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

19 Sep 2023 16:32:13 By Nasdaq GlobeNewswire